|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Fenoldopam#Adverse Reactions]] |
| {{Fenoldopam}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Adverse Reactions==
| |
| Adult Patients: Fenoldopam causes a dose-related fall in blood pressure and increase in heart rate (see Precautions, [[Tachycardia]], and [[Hypotension]]). In controlled clinical studies of severe [[hypertension]] in patients with end-organ damage, 3% (4/137) of patients withdrew because of excessive falls in blood pressure. Increased heart rate could, in theory, lead to ischemic cardiac events or worsened heart failure, although these events have not been observed. The most common events reported as associated with fenoldopam use are [[headache]], cutaneous dilation (flushing), [[nausea]], and [[hypotension]], each reported in more than 5% of patients.
| |
| | |
| ===Adverse reactions in controlled trials in hypertensive adult patients===
| |
| | |
| Adverse events occurring more than once in any dosing group (once if potentially important or plausibly drug-related) in the fixed-dose constant-infusion studies are presented in the following Table by infusion-rate group. There was no clear dose relationship, except possibly for [[headache]], [[nausea]], [[flushing]].
| |
| | |
| {|
| |
| |[[File:Fenoldopam01.jpg|thumb|800px]]
| |
| |}
| |
| | |
| ===Adverse effects in overall data base===
| |
| | |
| The adverse event incidences listed below are based on observations of over 1,000 fenoldopam treated adult patients and not listed in Table 4 above.
| |
| | |
| ===Events reported with a frequency between 0.5 to 5% in patients treated with IV fenoldopam===
| |
| | |
| '''Cardiovascular''': [[extrasystoles]], [[palpitations]], [[bradycardia]], [[heart failure]], [[ischemic heart disease]], [[myocardial infarction]], [[angina pectoris]]
| |
| | |
| '''Metabolic''': elevated BUN, elevated serum glucose, elevated transaminase, elevated LDH
| |
| | |
| '''General Body''': non-specific chest pain, [[pyrexia]]
| |
| | |
| '''Hematologic/Lymphatic''': [[leukocytosis]], bleeding
| |
| | |
| '''Respiratory''': [[dyspnea]], [[upper respiratory disorder]]
| |
| | |
| '''Genitourinary''': [[oliguria]]
| |
| | |
| '''Musculoskeletal''': limb cramp
| |
| | |
| Pediatric Patients: In pediatric patients, the most common adverse events reported during short-term administration in controlled trials (30 minutes) were [[hypotension]] and [[tachycardia]]. However, because of the short exposure, there is limited experience with defining adverse events in children. The long-term effects of fenoldopam on growth and development have not been studied.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = CORLOPAM (FENOLDOPAM MESYLATE) INJECTION, SOLUTION [HOSPIRA, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=df4cd207-c3b8-4008-5290-02f296c2b4a6 | publisher = | date = | accessdate = 26 February 2014 }}</ref>
| |
| | |
| == References ==
| |
| {{Reflist|2}}
| |
| | |
| {{Sympatholytic antihypertensives}}
| |
| {{Dopaminergics}}
| |
| | |
| [[Category:Benzazepines]]
| |
| [[Category:D1-receptor agonists]]
| |
| [[Category:Phenols]]
| |
| [[Category:Organochlorides]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |